跳至主要内容
临床试验/NCT02194361
NCT02194361已完成2 期

Efficacy of a Bilberry Extract Standardised to a Content of 25% Anthocyanosides in Improving the Night Vision of Healthy Volunteers: a Double-blind, Randomized, Placebo Controlled, Cross-over Trial Over 2 x 28 Days

Boehringer Ingelheim0 个研究点目标入组 119 人开始时间: 1999年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
119
主要终点
Change of the dark adaption of the pupil using the method of the dark adaption Goggles (DAG)

研究概览

简要总结

Study to determine the Efficacy of Standardised Bilberry Extract in improving the night vision and to evaluate its tolerability and safety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects (volunteers) with normal twilight and night vision
  • Age 18+, young and collaborative men or women
  • Having given their written informed consent
  • Full visual acuity (vision 0.8 or better) according to DIN Standard condition
  • Refraction ≤ +/-10.0 in the highest main step
  • Normal intraocular pressure (10-20 mmHg)

排除标准

  • Diabetes mellitus
  • Abnormal visual acuity or abnormal morphological eye findings
  • Glaucoma and macula degeneration
  • Disease of the retina
  • Consumption of anthocyan preparations during the past six months
  • Opthalmologic pathology: cataract, visus < 0.8, retinal pathology, maculopathy, intraocular pressure > 21 mmHg, known acute or chronic eye disease, use of hard contact lenses, eye surgery performed within the last 12 months
  • Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug: e.g. diabetes mellitus, anamnestic indications of diabetic microangiopathy or polyneuropathy, renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease (hypertension > 160/100 mmHg), psychiatric disorder, myasthenia gravis, delirious state, albino
  • Any treatment that might interfere with the evaluation of the test drug, in particular drugs with known influence on eye sight or adaptation (e.g. chloroquine, digitalis, ethambutol, chlorpromazine, benzodiazepines or phenothiazine derivatives such as thioridazine, periciazine, perphenazine)
  • Known hypersensitivity to any of the ingredients of the study drug
  • Drug and alcohol abuse
  • Pregnancy, lactation, women of childbearing potential who do not use an established contraceptive
  • Participation in another trial within the past 30 days

研究组 & 干预措施

Anthocyan capsules

Experimental

干预措施: Anthocyan capsules (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change of the dark adaption of the pupil using the method of the dark adaption Goggles (DAG)

时间窗: From day 1 to 28 and from day 57 to day 84

次要结局

  • Assessment of clinical global impression on a 5-point rating scale(Days 28 and 84)
  • Changes of the dark adaption using dark flashes(From day 1 to day 28 and from day 57 to day 84)
  • Assessment of subjective efficacy based on a visual analogue scale (VAS) rating questionnaire(pre-dose on day 1, day 28, pre-dose on day 57, day 84)
  • Changes of the weakest, correctly recognised contrast level(From day 1 to day 28 and from day 57 to day 84)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Efficacy of a Standardised Bilberry Extract in... | 临床试验